Metabolic Phenotypes-The Game Changer in Quality of Life of Obese Patients?
fat mass
metabolic syndrome
obesity phenotypes
quality of life
Journal
Healthcare (Basel, Switzerland)
ISSN: 2227-9032
Titre abrégé: Healthcare (Basel)
Pays: Switzerland
ID NLM: 101666525
Informations de publication
Date de publication:
25 Mar 2022
25 Mar 2022
Historique:
received:
28
02
2022
revised:
19
03
2022
accepted:
22
03
2022
entrez:
23
4
2022
pubmed:
24
4
2022
medline:
24
4
2022
Statut:
epublish
Résumé
The present study aimed to investigate the association of obesity phenotypes and quality of life (QoL) scales and their relationship with fat mass (FM) parameters. This study categorized 104 subjects into 4 obesity phenotypes based on BMI and metabolic syndrome status: metabolically healthy obese (MHO), metabolically unhealthy obese (MUO), metabolically healthy non-obese (MHNO), and metabolically unhealthy non-obese (MUNO). Body composition was measured by dual-energy X-ray absorptiometry (DEXA) and metabolic profile was characterized by blood samples. All subjects completed the SF-36 item Short Form Health Survey Questionnaire. Comparing the four obesity phenotypes, significant results were reported for Bodily Pain between MHNO/MUNO ( This study reported an inverse U-shaped relationship between FM and QoL in obesity phenotypes, suggesting that metabolic status is a key factor involved in modulating QoL and therefore challenging the idea of obesity as a main driver of low QoL. We recommend the inclusion of FM percentage in the definition of obesity phenotypes in future research, to better evaluate QoL of obesity phenotypes.
Sections du résumé
BACKGROUND
BACKGROUND
The present study aimed to investigate the association of obesity phenotypes and quality of life (QoL) scales and their relationship with fat mass (FM) parameters.
METHODS
METHODS
This study categorized 104 subjects into 4 obesity phenotypes based on BMI and metabolic syndrome status: metabolically healthy obese (MHO), metabolically unhealthy obese (MUO), metabolically healthy non-obese (MHNO), and metabolically unhealthy non-obese (MUNO). Body composition was measured by dual-energy X-ray absorptiometry (DEXA) and metabolic profile was characterized by blood samples. All subjects completed the SF-36 item Short Form Health Survey Questionnaire.
RESULTS
RESULTS
Comparing the four obesity phenotypes, significant results were reported for Bodily Pain between MHNO/MUNO (
CONCLUSION
CONCLUSIONS
This study reported an inverse U-shaped relationship between FM and QoL in obesity phenotypes, suggesting that metabolic status is a key factor involved in modulating QoL and therefore challenging the idea of obesity as a main driver of low QoL. We recommend the inclusion of FM percentage in the definition of obesity phenotypes in future research, to better evaluate QoL of obesity phenotypes.
Identifiants
pubmed: 35455798
pii: healthcare10040617
doi: 10.3390/healthcare10040617
pmc: PMC9025564
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
World J Gastroenterol. 2016 Jan 14;22(2):681-703
pubmed: 26811617
J Clin Med. 2021 Oct 30;10(21):
pubmed: 34768636
Clin Nutr. 2017 Jun;36(3):853-860
pubmed: 27184975
Med Sci Sports Exerc. 2000 Sep;32(9 Suppl):S498-504
pubmed: 10993420
J Clin Endocrinol Metab. 2006 Aug;91(8):2906-12
pubmed: 16735483
Diabetes. 2003 May;52(5):1104-10
pubmed: 12716739
Obes Sci Pract. 2018 Jul 25;4(5):417-426
pubmed: 30338112
Nutrients. 2016 Nov 25;8(12):
pubmed: 27897994
Obes Rev. 2014 Oct;15(10):781-90
pubmed: 25040597
Eur J Prev Cardiol. 2016 Jun;23(9):956-66
pubmed: 26701871
BMC Endocr Disord. 2021 Apr 28;21(1):85
pubmed: 33910543
BMC Public Health. 2012 Feb 24;12:143
pubmed: 22364437
Diabetologia. 2019 Apr;62(4):558-566
pubmed: 30569272
PLoS One. 2013 Oct 17;8(10):e76188
pubmed: 24146838
Metabolism. 2019 Aug;97:50-56
pubmed: 31071310
J Eval Clin Pract. 2009 Apr;15(2):328-34
pubmed: 19335493
Obesity (Silver Spring). 2013 Mar;21(3):E322-7
pubmed: 23592685
Qual Life Res. 2001;10(5):395-404
pubmed: 11763202
Diabetologia. 2021 Sep;64(9):1963-1972
pubmed: 34109441
Nutr J. 2020 Feb 25;19(1):19
pubmed: 32098622
Int J Environ Res Public Health. 2022 Jan 06;19(2):
pubmed: 35055447
J Clin Epidemiol. 1999 May;52(5):405-12
pubmed: 10360335
Ann Intern Med. 1993 Apr 15;118(8):622-9
pubmed: 8452328
J Epidemiol Community Health. 2014 May;68(5):471-7
pubmed: 24385547
Health Qual Life Outcomes. 2004 Dec 09;2:70
pubmed: 15588308
Circulation. 2005 Oct 25;112(17):2735-52
pubmed: 16157765
Lancet Diabetes Endocrinol. 2018 Sep;6(9):714-724
pubmed: 29859908
Int J Obes (Lond). 2012 Feb;36(2):286-94
pubmed: 21587201
Eur J Pain. 2013 Oct;17(9):1316-26
pubmed: 23576531
J Clin Invest. 2019 Oct 1;129(10):3978-3989
pubmed: 31524630
Circulation. 2018 Apr 10;137(15):1543-1545
pubmed: 29632150
Qual Life Res. 2011 Jun;20(5):665-74
pubmed: 21547358
J Public Health Med. 1999 Dec;21(4):372-6
pubmed: 11469357